ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant

Q. Xu1, A. Skaro2, V. C. McAlister2

1Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, 2Surgery, London Health Science Center, London, ON, Canada

Meeting: 2019 American Transplant Congress

Abstract number: 436

Keywords: Antibodies, Graft survival, HLA antibodies, Liver transplantation

Session Information

Session Name: Concurrent Session: Liver Transplant Complications and Retransplantation II

Session Type: Concurrent Session

Date: Tuesday, June 4, 2019

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Ballroom A

*Purpose: Recent reports indicated important while inconsistent roles of preformed donor specific antibody (DSA) to HLA in liver transplantation. Re-transplant liver patients were understudied due to worse outcome than 1st graft. Auto antibodies to Angiotensin II Type I Receptor (AT1R) have been reported to be detrimental for survival of kidney transplant but weren’t studied in liver transplantation. In this study, we try to determine the roles of preformed DSA and anti-AT1R auto antibodies in long-term survival of 2nd liver transplant.

*Methods: We retrospectively reviewed patients (1991-2018) undergoing a 2nd liver transplantation in our centre with available pre-operative serum and donor HLA typing. Patients who received ABO incompatible, multiple organ transplants or incomplete demographics were excluded. Banked sera were tested for anti-HLA antibodies with Luminex-based solid phase assays. Anti-AT1R antibodies were tested with ELISA kit. All statistical analyses were done with IBM SPSS version 25.

*Results: We included 94 patients in this study. With long follow-up up to 25 years, 48 (51.1%) patients had lost 2nd liver transplant. Preformed DSA to 2nd liver transplant were found in 34 (36.2%) patients. Surprisingly, 48 (51.1%) patients had positive anti-AT1R antibody >17U/ml; 22 (23.4%) had anti-AT1R antibody>40U/ml so extra dilutions were performed for accurate measurement. When backward stepwise methods were used to select covariates in multivariate cox regression, only three variables were left in model: MELD (Model for End-Stage Liver Disease) Score [HR=1.061 (1.019-1.105), p=0.004] and AT1R antibody>40U/ml [HR=2.241 (1.125-4.467), p=0.02] were significant risk factors for survival of the 2nd liver transplant; there was non-significant trend toward worse graft survival in male patients [HR=1.92(0.917-4.024), p=0.08]. Class, loci, strength of DSA, other patient/donor characteristics such as age, primary diseases, causes of loss 1st graft, survival of 1st graft, cold ischemia time were found to be insignificant for liver graft survival. MELD score [AUC=0.700(0.577-0.823), p=0.004] and AT1R antibody [AUC=0.64(0.528-0.753), p=0.02] quantitatively predicted graft loss in receiver operating characteristic analysis. Patients with AT1R antibody>40U/ml had significant worse survival of 2nd liver graft (p=0.035) in Kaplan-Meier analysis (Figure below).

*Conclusions: High MELD score and anti-AT1R antibody, not preformed DSA, were found to be associated with inferior outcomes of 2nd liver transplant.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Xu Q, Skaro A, McAlister VC. MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/meld-score-and-anti-angiotensin-receptor-antibody-predict-long-term-survival-of-liver-re-transplant/. Accessed May 11, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences